John D. Isaacs BSc, MBBS, PhD

John Isaacs is Professor of Clinical Rheumatology at Newcastle University and a consultant rheumatologist at the Freeman Hospital, Newcastle-upon-Tyne, UK. Over the past 25 years, his work has focused on the potential of novel immunotherapies to treat rheumatoid arthritis (RA), ranging from target identification to early- and late-stage clinical trials. He has performed several pioneering experimental medicine studies in patients with inflammatory disease, challenging existing dogma and informing the design of subsequent generations of therapeutic agents. In 1992 he was the first to demonstrate immunogenicity of a humanised therapeutic antibody, CAMPATH-1H (Lancet). Professor Isaacs directs Newcastle University’s Institute for Cellular Medicine (the largest Institute in the Medical Faculty), and runs a research group focussed on therapeutic tolerance induction.